BioXcel Therapeutics Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics or view top-rated stocks.

5 Wall Street research analysts have issued 1-year target prices for BioXcel Therapeutics' shares. Their BTAI stock forecasts range from $24.00 to $110.00. On average, they predict BioXcel Therapeutics' share price to reach $65.00 in the next twelve months. This suggests a possible upside of 429.7% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics or view top-rated stocks among Wall Street analysts.

BioXcel Therapeutics' stock was trading at $20.33 at the beginning of the year. Since then, BTAI shares have decreased by 39.6% and is now trading at $12.27.
View the best growth stocks for 2022 here.

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for BioXcel Therapeutics.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) released its quarterly earnings data on Monday, May, 9th. The company reported ($1.12) EPS for the quarter, beating analysts' consensus estimates of ($1.21) by $0.09. During the same period in the prior year, the firm earned ($1.08) EPS.
View BioXcel Therapeutics' earnings history.

Some companies that are related to BioXcel Therapeutics include Sierra Oncology (SRRA), BridgeBio Pharma (BBIO), Day One Biopharmaceuticals (DAWN), Zentalis Pharmaceuticals (ZNTL), Agios Pharmaceuticals (AGIO), Prothena (PRTA), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), Cassava Sciences (SAVA), Amylyx Pharmaceuticals (AMLX), IVERIC bio (ISEE), Kura Oncology (KURA), Reata Pharmaceuticals (RETA), Arcutis Biotherapeutics (ARQT) and 23andMe (ME).
View all of BTAI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

BioXcel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (5.10%), State Street Corp (5.01%), BlackRock Inc. (4.58%), Vanguard Group Inc. (3.79%), Massachusetts Financial Services Co. MA (1.52%) and Bank of America Corp DE (0.70%). Company insiders that own BioXcel Therapeutics stock include Bioxcel Llc, Frank Yocca, Peter Mueller, Vimal Mehta and Vincent O'neill.
View institutional ownership trends for BioXcel Therapeutics.

BTAI stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, BlackRock Inc., HITE Hedge Asset Management LLC, Metropolitan Life Insurance Co NY, California State Teachers Retirement System, DAVENPORT & Co LLC, and Simplex Trading LLC. Company insiders that have sold BioXcel Therapeutics company stock in the last two years include Bioxcel Llc, Frank Yocca, Vimal Mehta, and Vincent O'neill.
View insider buying and selling activity for BioXcel Therapeutics or view top insider-selling stocks.

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, State Street Corp, Jane Street Group LLC, Bank of America Corp DE, Apis Capital Advisors LLC, Vanguard Group Inc., Graham Capital Management L.P., and PDT Partners LLC.
View insider buying and selling activity for BioXcel Therapeutics or or view top insider-buying stocks.

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BTAI stock can currently be purchased for approximately $12.27.

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $343.44 million. The company earns $-106.93 million in net income (profit) each year or ($4.12) on an earnings per share basis.

BioXcel Therapeutics employs 89 workers across the globe.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at [email protected].